Compare Match Group Inc (MTCH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Tango Therapeutics Inc. — how do they compare? Match Group Inc trades at $42.37 (market cap $9.73B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Match Group Inc is far larger — about 2.6× Tango Therapeutics Inc.'s market cap, and Match Group Inc pays a 1.89% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Tango Therapeutics Inc. for 0 Days on average.
| MTCH | TNGX | |
|---|---|---|
Market Cap | $9.73B | $3.74B |
Volume | 2,279,934 | 3,438,781 |
Sector | Media | Health |
52-Week High | $44.40 | $32.90 |
52-Week Low | $28.90 | $7.50 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $12.70B | $2.76B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Match Group (MTCH) trades at $42.36, up 2.02% today, with a bullish technical signal and strong cash flow growth. The stock shows solid fundamentals with a P/E of 15.04 and net income margin of 20.17%. Recent earnings have been mixed, beating in Q2 2026 but missing in Q1 2026, while analyst consensus remains positive with a $42.29 price target. News highlights product innovation and institutional buying interest.
The outlook for MTCH is cautiously optimistic, supported by margin expansion and Hinge's growth, but risks include high debt levels and competitive pressures. Upside potential exists if Tinder's turnaround gains momentum, though investor sentiment is tempered by recent volatility and macroeconomic uncertainties.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
